Malignant Neoplasms of Lip (ICD-11: 2B60) - Complete Clinical Coding Guide
1. Introduction
Malignant neoplasms of the lip represent an important group of tumors that originate from the labial transitional epithelium or underlying anatomical structures, such as the orbicularis oris muscle. These lesions occupy a singular position in head and neck oncology, differentiating themselves from both cutaneous neoplasms and lesions of the oral mucosa proper.
The clinical importance of malignant neoplasms of the lip resides in their exposed anatomical location, which frequently allows early detection through direct visual inspection. This characteristic contributes to a generally more favorable prognosis when compared to other neoplasms of the head and neck region. Chronic solar exposure constitutes the main risk factor for these lesions, especially in the lower lip, which receives greater ultraviolet radiation.
From an epidemiological perspective, these neoplasms present variable distribution according to different populations and patterns of environmental exposure. Professionals who work outdoors, individuals with fair skin, and smokers present increased risk. The impact on public health is significant, considering not only the associated morbidity and mortality, but also the functional and aesthetic consequences that affect quality of life, verbal communication, and feeding.
Correct coding using ICD-11 is critical for multiple aspects: adequate epidemiological surveillance, resource planning in oncology, international comparative studies, allocation of specialized treatments, and accurate documentation for medico-legal purposes. Clear distinction between neoplasms of the lip and other adjacent lesions ensures reliable statistical data and appropriate clinical management.
2. Correct ICD-11 Code
Code: 2B60
Description: Malignant neoplasms of the lip
Parent category: Malignant neoplasms of the lip, oral cavity or pharynx
Official definition: Malignant neoplasms originating from the transitional epithelium of the lip (excluding oral mucosa and skin of the external lip) or from underlying anatomical structures (for example, orbicularis oris muscle).
The definition establishes precise anatomical boundaries that are fundamental for correct coding. The labial transitional epithelium, also known as the vermilion zone or semimucosa, represents the specific region between the external keratinized skin and the internal moist oral mucosa. This zone has unique histological characteristics, being covered by stratified squamous epithelium with variable keratinization and rich vascularization that gives it its characteristic coloration.
The explicit exclusion of oral mucosa and external lip skin is essential for diagnostic differentiation. Lesions that originate primarily in the external labial skin are classified as cutaneous neoplasms, while those of the internal oral mucosa receive specific coding for oral mucosa. Code 2B60 also encompasses tumors that originate from structures underlying the transitional epithelium, including the orbicularis oris muscle, minor salivary glands, and local connective tissue.
This precision in definition allows uniformity in international classification, facilitating epidemiological comparisons and multicenter studies on treatment and prognosis.
3. When to Use This Code
Code 2B60 should be applied in specific clinical situations that meet the established anatomical and histopathological criteria:
Scenario 1: Squamous cell carcinoma of the lower lip vermilion Patient presents with an ulcerated lesion of progressive growth located in the semimucosa of the lower lip, confirmed histopathologically as squamous cell carcinoma. The biopsy demonstrates origin in the transitional epithelium, without extension to external skin or internal oral mucosa. This is the most common scenario for use of code 2B60, especially in individuals with a history of chronic sun exposure.
Scenario 2: Basal cell carcinoma of the lip with origin in the transition zone Nodular lesion with central ulceration located precisely in the vermilion zone, with histological confirmation of basal cell carcinoma originating from the labial transitional epithelium. Although less frequent than squamous cell carcinoma at this location, when documented in the transition zone, code 2B60 is used.
Scenario 3: Malignant neoplasm of the orbicularis oris muscle Primary malignant tumor originating in the orbicularis oris muscle, without evidence of cutaneous or mucosal origin. May include sarcomas or other mesenchymal neoplasms specific to this anatomical structure when classified as malignant neoplasms of the lip.
Scenario 4: Carcinoma of minor salivary glands of the lip Malignant neoplasm originating in the minor salivary glands located in the submucosal layer of the lip, in the vermilion region. Examples include adenoid cystic carcinoma or mucoepidermoid carcinoma with confirmed origin in the labial glands.
Scenario 5: Malignant melanoma of the labial semimucosa Melanoma originating from melanocytes present in the transitional epithelium of the lip, with histopathological and immunohistochemical confirmation. Documentation must clearly specify the origin in the vermilion zone, differentiating from cutaneous melanomas.
Scenario 6: Local recurrence of previously treated malignant neoplasm of the lip Patient with a history of previous treatment of malignant neoplasm of the lip who presents with confirmed local recurrence at the same anatomical location (transition zone), without evidence of distant metastasis. Code 2B60 remains appropriate for local recurrence.
In all these scenarios, histopathological confirmation is essential, as is clear documentation of the precise anatomical location of the primary lesion.
4. When NOT to Use This Code
The correct application of code 2B60 requires knowledge of exclusion situations:
Primary mesenchymal neoplasms: When the neoplasm is classified as mesenchymal according to specific histopathological criteria, code 1706880799 should be used. This distinction is fundamental, as mesenchymal neoplasms have different biological behavior, treatment, and prognosis compared to epithelial neoplasms.
Neoplasms of lip skin: Lesions that originate primarily in the external skin of the lip, including cutaneous basal cell and squamous cell carcinomas, should be coded as malignant neoplasms of lip skin (code 1965082709). The differentiation is based on histological origin in the keratinized epidermis of the skin, not in the transitional epithelium.
Neoplasms of oral mucosa: Tumors that originate in the wet oral mucosa, even when close to the lip, should not receive code 2B60. These lesions have specific coding within neoplasms of the oral cavity.
Metastases to the lip: When a malignant neoplasm from another primary site metastasizes to the lip, the appropriate code is that of the primary neoplasm, with additional specification of the metastatic site. Code 2B60 is reserved for primary neoplasms of the lip.
Premalignant lesions: Conditions such as actinic cheilitis, leukoplakia, or epithelial dysplasia of the lip should not be coded as 2B60, as they do not represent established malignant neoplasms, although they may progress to malignancy.
Secondary extension from adjacent tumors: When a malignant neoplasm of another structure (such as nasal cavity, facial skin, or oral mucosa) secondarily invades the lip, the primary code should reflect the site of origin, not the lip as the invaded structure.
Clear differentiation between these situations ensures accuracy in coding and avoids statistical confusion that could compromise epidemiological studies and public health planning.
5. Coding Step by Step
Step 1: Assess diagnostic criteria
The diagnostic confirmation of malignant neoplasm of the lip requires a systematic approach. Begin with a detailed clinical history investigating risk factors: chronic sun exposure, smoking, alcohol use, history of premalignant lesions, and previous treatments. Physical examination should include meticulous inspection of the lip under good lighting, palpation to assess depth and fixation, and complete examination of the oral cavity and cervical lymph node chains.
Biopsy is the diagnostic gold standard. It can be excisional for small lesions or incisional for larger lesions. The specimen must be adequately fixed and sent for histopathological analysis with complete clinical information. The histopathology report should specify: histological type, degree of differentiation, depth of invasion, margin involvement, and lymphovascular or perineural invasion.
Complementary imaging studies include cervical ultrasound for lymph node evaluation, computed tomography or magnetic resonance imaging for local staging and assessment of bone invasion or deep structure involvement. In selected cases, positron emission tomography may aid in detection of distant metastases.
Step 2: Verify specifiers
After diagnostic confirmation, document important specifiers: precise location (upper lip, lower lip, or commissure), laterality (right, left, or central), lesion dimensions, complete TNM staging, presence of regional or distant lymph node metastases, and specific histological type.
TNM staging is essential: T refers to the size of the primary tumor, N to regional lymph node involvement, and M to the presence of distant metastases. This information guides treatment and prognosis and should be documented along with code 2B60.
Histological subtypes should be specified when possible: squamous cell carcinoma (most common), basal cell carcinoma, verrucous carcinoma, melanoma, minor salivary gland carcinomas, among others. Each subtype has specific prognostic and therapeutic implications.
Step 3: Differentiate from other codes
2B61 - Malignant neoplasms of the base of tongue: The fundamental difference lies in anatomical location. While 2B60 refers to the lip (vermilion zone and underlying structures), 2B61 specifies tumors of the base of the tongue, the posterior region of the organ near the oropharynx. Clinically, base of tongue tumors present with more prominent dysphagia and odynophagia, while lip tumors are visible and palpable externally.
2B62 - Malignant neoplasms of other or unspecified parts of the tongue: This code encompasses tumors of the tongue body (anterior two-thirds) and unspecified locations. Differentiation from 2B60 is clear by the anatomical structure involved: tongue versus lip. Lingual tumors affect tongue mobility and speech articulation differently than lip tumors.
2B63 - Malignant neoplasms of the gingiva: Refers to tumors of gingival tissue (maxillary or mandibular). Differentiation from 2B60 is based on anatomical origin: gingiva (tissue covering the alveolar processes) versus lip (labial transition zone). Gingival tumors frequently present with early bone involvement and periodontal symptoms.
Step 4: Required documentation
Mandatory documentation checklist:
- Complete patient identification
- Date of histopathological diagnosis
- Lesion description (precise location, dimensions, characteristics)
- Complete histopathology report with histological type
- TNM staging
- Identified risk factors
- Imaging studies performed and results
- Relevant comorbidities
- Previous treatments if applicable
The record should clearly specify that the neoplasm originates in the transitional epithelium of the lip or underlying structures, differentiating from external skin or oral mucosa. This anatomical precision is fundamental to justify the use of code 2B60.
6. Complete Practical Example
Clinical Case:
A 62-year-old male patient, farmer with 40 years of occupational sun exposure, presents with a lesion on the lower lip with six months of evolution. He reports 30 pack-years of smoking and denies alcohol use. He initially noticed a hardened, scaly area that progressed with ulceration and occasional bleeding. He denies significant pain, dysphagia, or speech alterations.
On physical examination, he presents with an ulcerated lesion measuring 1.8 cm in greatest diameter located on the vermilion border of the lower lip, left paramedian region, with raised and hardened edges, infiltrated base, and bleeding on manipulation. The lesion is specifically located in the vermilion zone, without visible extension to external skin or internal oral mucosa. Cervical palpation reveals a mobile left submandibular lymph node measuring 1.2 cm. Remainder of oral cavity examination unremarkable.
Incisional biopsy was performed demonstrating moderately differentiated squamous cell carcinoma with invasion into deep connective tissue. Cervical ultrasound confirmed left submandibular lymph node with suspicious characteristics. Computed tomography of face and neck showed no mandibular bone invasion, confirmed 1.8 cm lesion on lower lip with extension to orbicularis oris muscle, and ipsilateral submandibular lymphadenopathy. Chest computed tomography without evidence of pulmonary metastases.
Step-by-Step Coding:
Criteria analysis:
- Histopathologic confirmation of squamous cell carcinoma
- Precise location in the vermilion zone of the lower lip (transitional epithelium)
- Invasion of underlying structure (orbicularis oris muscle)
- No origin from external skin or internal oral mucosa
- Primary tumor (non-metastatic)
Code selected: 2B60 - Malignant neoplasms of lip
Complete justification: Code 2B60 is appropriate because the neoplasm originated from the transitional epithelium of the lower lip (vermilion zone), as confirmed by biopsy and imaging studies. The code definition specifies neoplasms originating from the transitional epithelium of the lip or underlying structures, including the orbicularis oris muscle, which corresponds exactly to the case presented.
The lesion did not originate from the external skin of the lip (which would indicate code 1965082709) nor from the oral mucosa (which would have another specific code). The histologic type (squamous cell carcinoma) is compatible with malignant neoplasms of the lip. Invasion of the orbicularis oris muscle is explicitly included in the definition of code 2B60.
Complementary codes:
- Staging: T2N1M0 (should be documented)
- Specification: Moderately differentiated squamous cell carcinoma
- Location: Lower lip, left paramedian
- Risk factors: Chronic occupational sun exposure, smoking
7. Related Codes and Differentiation
Within the Same Category:
2B61: Malignant neoplasms of the base of tongue
Use 2B61 when: The neoplasm originates at the base of the tongue (posterior third), a region extending posteriorly to the circumvallate papillae to the vallecula and including lingual tonsils. Patients typically present with dysphagia, odynophagia, referred otalgia, and palpable mass in the oropharynx.
Use 2B60 when: The neoplasm is located on the lip (vermillion zone), an anatomical structure completely different, externally visible, with clinical presentation of visible and palpable labial lesion.
Main difference: Distinct anatomical location (base of tongue versus lip) with different clinical presentations, risk factors, and therapeutic approaches.
2B62: Malignant neoplasms of other parts or unspecified parts of the tongue
Use 2B62 when: The neoplasm affects the body of the tongue (anterior two-thirds), lateral borders, dorsal or ventral surface of the tongue, or when the specific location on the tongue is not determined. Symptoms include difficulty with lingual mobility, speech articulation changes, and dysphagia.
Use 2B60 when: The neoplasm is clearly located on the lip, not on the tongue. Physical examination and imaging studies demonstrate labial origin.
Main difference: Anatomical structure involved (tongue versus lip), with different functional implications, lymphatic drainage patterns, and surgical strategies.
2B63: Malignant neoplasms of the gingiva
Use 2B63 when: The neoplasm originates in gingival tissue (maxillary or mandibular), frequently with underlying bone involvement, dental mobility, and periodontal symptoms. The lesion is located over the alveolar process.
Use 2B60 when: The origin is on the lip (vermillion zone), without primary gingival involvement. Even if there is anatomical proximity, the origin determines the code.
Main difference: Anatomical location (gingiva versus lip) and invasion pattern (early bone invasion in gingival tumors versus muscular invasion in labial tumors).
Differential Diagnoses:
Conditions that may be confused with malignant neoplasms of the lip include: actinic cheilitis (pre-malignant lesion), chronic traumatic ulcers, recurrent herpes labialis, angular cheilitis, pyogenic granuloma, and lichen planus. Differentiation requires biopsy for histopathological confirmation of malignancy.
8. Differences with ICD-10
In ICD-10, malignant neoplasms of the lip were coded as C00, with subdivisions for upper lip (C00.0), lower lip (C00.1), labial commissure (C00.6), and other locations. The code C00.9 was used for unspecified lip.
The main change in ICD-11 with code 2B60 is the emphasis on precise anatomical definition, clearly specifying that it refers to the transitional epithelium of the lip and underlying structures, with explicit exclusions of external skin and internal oral mucosa. This precision reduces ambiguities in coding.
ICD-11 also presents a clearer hierarchical structure, with more specific subcategories and better integration with oncologic staging systems. Alphanumeric coding (2B60) replaces the numeric coding of ICD-10 (C00), facilitating future expansion of the system.
The practical impact includes greater precision in epidemiological data collection, improved international comparability, and reduction of variability in coding among different professionals and institutions. Health systems that migrate from ICD-10 to ICD-11 should implement specific training to ensure adequate transition, especially in understanding more precise anatomical definitions.
9. Frequently Asked Questions
How is malignant neoplasm of the lip diagnosed?
Diagnosis is based on clinical evaluation followed by histopathological confirmation. Physical examination identifies suspicious lesions on the lip, characterized by persistent ulceration, induration, bleeding, or progressive growth. Biopsy is mandatory for confirmation, and may be excisional (complete removal of small lesion) or incisional (sampling of larger lesion). The material is analyzed microscopically to identify malignant cells, histological type, and degree of differentiation. Complementary examinations such as computed tomography or magnetic resonance imaging assess local extension and involvement of adjacent structures.
Is treatment available in public health systems?
Yes, treatment of malignant neoplasms of the lip is generally available in public health systems in most countries, being considered an essential part of oncological care. Treatment may include surgery, radiotherapy, chemotherapy, or combinations, depending on staging. Surgery is often the primary treatment for early-stage lesions, with reconstructive techniques available for functional and aesthetic preservation. Specialized head and neck oncology centers offer a multidisciplinary approach including surgeons, oncologists, radiation therapists, speech-language pathologists, and nutritionists.
How long does treatment last?
Duration varies significantly according to staging and therapeutic modality. Surgeries for early-stage lesions can be performed in a single procedure, with recovery lasting several weeks. Adjuvant or primary radiotherapy typically extends for 5-7 weeks with daily sessions. Advanced cases may require combined treatment extending over several months. Post-treatment follow-up is prolonged, generally with frequent evaluations in the first two years (every 2-3 months) and subsequently at longer intervals, extending for at least five years to monitor for recurrence.
Can this code be used in medical certificates?
Yes, code 2B60 can and should be used in official medical documentation, including certificates, when appropriate. However, medical confidentiality considerations must be observed. In certificates for employment or administrative purposes, one may opt for more generic descriptions such as "malignant neoplasm" without specifying location, respecting patient privacy. For documentation in medical records, detailed medical reports, and communication among healthcare professionals, the complete code should be used for diagnostic accuracy. The decision regarding the level of detail in certificates should consider the purpose of the document and patient consent.
What are the main risk factors for malignant neoplasms of the lip?
Chronic sun exposure constitutes the main risk factor, especially ultraviolet radiation accumulated over decades. Outdoor workers present elevated risk. Fair skin phototypes (lower tanning capacity, greater tendency to sunburn) confer greater susceptibility. Smoking, especially pipe smoking, significantly increases risk. Chronic alcohol use is also associated. Immunosuppression, whether from medications or medical conditions, elevates risk. History of premalignant lesions such as actinic cheilitis or labial leukoplakia represents an important risk factor. Occupational exposure to certain chemical agents may contribute.
Can malignant neoplasms of the lip be prevented?
Yes, preventive measures are effective. Labial photoprotection with specific sunscreens (high SPF, frequent reapplication) reduces ultraviolet exposure. Use of wide-brimmed hats and avoiding sun exposure during peak hours (10 AM-4 PM) are recommended. Smoking cessation eliminates an important risk factor. Moderation in alcohol consumption contributes to risk reduction. Appropriate treatment of premalignant lesions such as actinic cheilitis can prevent progression to malignancy. Periodic examinations in high-risk individuals allow early detection. Education about labial self-examination facilitates identification of suspicious lesions at early stages.
What is the prognosis for patients with malignant neoplasm of the lip?
The prognosis is generally favorable when compared to other head and neck neoplasms, especially in cases diagnosed early. Small, well-differentiated lesions without lymph node involvement present high cure rates with appropriate treatment. Staging is the main prognostic factor: T1-T2 tumors without lymph node metastases have excellent prognosis, while advanced lesions (T3-T4) or with lymph node metastases present more guarded prognosis. Histological type also influences prognosis: well-differentiated squamous cell carcinomas have better prognosis than poorly differentiated variants or aggressive histological types. Favorable anatomical location allows early detection and complete resection with adequate margins, contributing to good outcomes.
How to differentiate a benign lesion from a malignant neoplasm on the lip?
Characteristics suggestive of malignancy include: persistent ulceration (does not heal in 2-3 weeks), elevated and indurated borders, infiltrated and fixed base, spontaneous bleeding or bleeding with minimal manipulation, progressive growth, color alteration (erythematous or leukoplastic areas), asymmetry, and loss of normal labial architecture. Benign lesions typically present regular borders, soft consistency, absence of deep infiltration, and may regress spontaneously or with simple treatment. However, definitive differentiation requires biopsy, as clinical characteristics may overlap. Any persistent labial lesion, especially in patients with risk factors, should be evaluated by a specialist and, when indicated, submitted to biopsy for definitive diagnosis. The fundamental rule is: lesions that do not heal in three weeks deserve further investigation.
Conclusion: Appropriate coding of malignant neoplasms of the lip using ICD-11 code 2B60 requires precise understanding of anatomical definitions, diagnostic criteria, and differentiation of related conditions. Correct application of this code contributes to effective epidemiological surveillance, health resource planning, and appropriate clinical documentation, benefiting both health systems and patients through accurate data that guide public policies and allocation of specialized treatments.
External References
This article was prepared based on reliable scientific sources:
- 🌍 WHO ICD-11 - Malignant neoplasms of lip
- 🔬 PubMed Research on Malignant neoplasms of lip
- 🌍 WHO Health Topics
- 📊 Clinical Evidence: Malignant neoplasms of lip
- 📋 Ministry of Health - Brazil
- 📊 Cochrane Systematic Reviews
References verified on 2026-02-03